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Background
Pulmonary embolism (PE) is a detrimental life-threatening event 
that accounts for 5 to 10 percent of  deaths among hospitalized 
patient [1]. Antithrombotic therapy for such disease was used to 
decrease early morbidity and mortality and to prevent recurrence 
without causing excessive bleeding. LMWH has been used for the 
treatment of  pulmonary embolism and proved to be effective but 
it lacks a test for follow up the therapeutic level of  the drug. The 
plasma anti-Xa assay is a laboratory test that indirectly measures 
the activity of  heparins and has been used most commonly to fol-
low up patients treated with low molecular weight heparins.
The mechanism by which anti-Xa assay determines the antico-
agulant activity is through measuring the ability of  the heparin-
antithrombin (AT) complex to inhibit activated factor X [2] and 
by using a special chromogenic procedure involving commercially 
available multi calibration kits, the residual amount of  factor Xa 
is calculated and inversely correlated to the amount of  heparin 
in the plasma. Anti-Xa activity results are expressed as units/ml.
When using enoxaparin at a twice-daily dose, the target peak plas-
ma concentration of  anti-Xa should be kept between 0.5–1.2 IU/
mL [3].
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Abstract
Background: Enoxaparin is one of  the LMWH that has been used for long time in the treatment of  acute pulmonary embolism. 
In this study, we will monitor anticoagulant therapy by anti-Xa assay and correlate its level to the efficacy and safety of  enoxaparin 
in the treatment of  pulmonary embolism.
Methods: The study was conducted on 42 patients in ICU diagnosed to have pulmonary embolism by CT pulmonary angiogra-
phy and treated by subcutaneous enoxaparin 1 mg/kg every 12 hours. Anticoagulant therapy was followed by anti-Xa assay done 
4 hours after the third dose of  subcutaneous enoxaparin and the results were correlated to the clinical outcome of  the patients 
as regards complications (recurrent pulmonary embolism, bleeding, low platelet count and death).
Results: According to anti-Xa assay, we divided the patients into three groups. Group I with anti-Xa level < 0.5 IU/mL, group II 
with anti-Xa level ≥ 0.5 and < 1.2 IU/mL and group III with anti-Xa level ≥ 1.2 IU/mL. 9 patients were in group I, 22 patients 
were in group II and 11 patients were in group III. 
There was no significant difference between the three groups as regards age, sex, BMI and underlying risk factors for pulmonary 
embolism. Serum creatinine level and pulmonary artery pressure were significantly higher in group I than in group II and III.
The incidence of  recurrent pulmonary embolism was significantly higher in group I than in group II and III with 7 out of  9 
patients in group I had recurrent pulmonary embolism compared with only 4 out of  22 and 1 out of  9 in group II and III re-
spectively. The mortality rate was significantly higher in group I than in group II and III with 3 recorded death cases in group I 
compared with zero recorded cases in group II and III. There was no significant difference between the three groups as regards 
thrombocytopenia and major bleeding complications. 
Conclusion: Anti-Xa assay is a good and reliable test for monitoring the efficacy of  LMWH therapy using enoxaparin for pa-
tients with pulmonary embolism as regards recurrence and mortality rates of  pulmonary embolism but it will not monitor safety 
of  enoxaparin therapy as regards incidence of  thrombocytopenia and bleeding complications.
The study was registered on www.clinicaltrials.gov, Registration ID: NCT02977013. Registered November 27, 2016.
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The therapeutic ranges of  LMWHs using anti-Xa assay have been 
determined for the treatment of  deep-vein thrombosis [4] and 
has been correlated with clinical outcome in acute Coronary Syn-
drome activity [5]. However no study has been done correlating 
anti-Xa assay with the clinical outcome of  patients with pulmo-
nary embolism treated with LMWH.
The aim of  the present study is to monitor anticoagulant therapy 
by anti-Xa assay and correlate its level to the efficacy and safety of  
enoxaparin in the treatment of  pulmonary embolism.
Methods
The study was registered on www.clinicaltrials.gov, Registration 
ID: NCT02977013, principal investigator’s name: Mohamed 
Sayed Mohamed Abbas, Registered November 27, 2016.
This prospective double blind observational trial was conducted 
on 42 patients in ICU aged 18 years or older and diagnosed to 
have pulmonary embolism and confirmed by the presence of  in-
traluminal filling defect in CT pulmonary angiography and treated 
with subcutaneous enoxaparin 1 mg/kg/12 hours. The study was 
conducted from August 2013 to September 2016.
Patients were excluded from this study if  they underwent throm-
bolysis, embolectomy or if  they are unfit for anticoagulant therapy 
because of  major bleeding or thrombocytopenia (a platelet count 
below 100,000 per cubic millimeter). Patients were also excluded 
if  they had impaired kidney function with a serum creatinine level 
above 2 mg/dl or uncontrolled hypertension (blood pressure > 
160/100 mmHg).
Written informed consent had been obtained from the patient 
families and the protocol was approved by the institution.
Anti-Xa Assay
In our study, blood sampling for anti-Xa assay was done 4 hours 
after the third dose of  subcutaneous enoxaparin. The timing of  
sampling was determined depending on the fact that LMWH half  
life in adults is ranging from 4-6 hours and the steady state con-
centration is reached within one day.
The conventional therapeutic range of  anti-Xa levels for patients 
treated with LMWH enoxaparin is considered according to litera-
tures to be between 0.5 IU/mL and 1.2 IU/ml [3].
Three groups of  patients were specified according to their anti-
Xa levels. The first group consisted of  patients with an anti-Xa 
activity < 0.5 IU/mL, which was considered as sub therapeutic 
according to the predefined therapeutic range. The second group 
of  patients had anti-Xa levels within the therapeutic range, ie, ≥ 
0.5 IU/mL and < 1.2 IU/mL. The third group consisted of  pa-
tients with anti-Xa levels ≥ 1.2 IU/mL. Care was taken for the 
patients with anti-Xa levels ≥ 1.8 IU/ml as it might be associated 
with more bleeding complications [6].
Clinical Follow-Up
All the patients were examined daily over a period of  4 weeks 
for symptoms and signs of  recurrent pulmonary embolism, Plate-
let count, bleeding and death events. Recurrent pulmonary em-
bolism was confirmed if  the repeat CT angiography revealed a 
new sudden arterial branch cutoff  or a new intraluminal filling 
defect that was not present on the first angiogram. Patients with 
platelet count less than 50,000/mm3 or those with bleeding and 
platelet count between 50,000 and 100,000/mm3 were considered 
to have severe thrombocytopenia. Bleeding is defined as major 
overt bleeding requiring blood transfusion > 2 units or marked 
hemoglobin drop > 2 gm/dl or if  the bleeding was intracranial 
or retroperitoneal. Death is defined as all deaths occurring within 
the 4 weeks of  the study. All these results were correlated to anti-
Xa assay.
Statistical Analysis
Data were analyzed using SPSS version 16.0 computer software 
(Chicago, IL, USA). Numerical variables were presented as mean 
and standard deviation (SD), and analyzed using Kruskal–Wallis 
test; while categorical variables were presented as frequency (%), 
and analyzed using chi-square test for trend. A P-value of  0.05 
was considered statistically significant.
Results
According to anti-Xa assay, we divided the patients into three 
groups. Group I with anti-Xa level < 0.5 IU/mL, group II with 
anti-Xa level ≥ 0.5 and < 1.2 IU/mL and group III with anti-Xa 
level ≥ 1.2 IU/mL. 9 patients were in group I, 22 patients were in 
group II and 11 patients were in group III. 
There was no significant difference between the three groups as 
regards age, sex, BMI and underlying risk factors for pulmonary 
embolism. Serum creatinine level and pulmonary artery pressure 
were significantly higher in group I than in group II and III (Table 
1, Table 2).
The incidence of  recurrent pulmonary embolism was significantly 
higher in group I than in group II and III with 7 out of  9 patients 
in group I had recurrent pulmonary embolism compared with 
only 4 out of  22 and 1 out of  9 in group II and III respective-
ly. The mortality rate was significantly higher in group I than in 
group II and III with 3 recorded death cases in group I compared 
with zero recorded cases in group II and III. There was no sig-
nificant difference between the three groups as regards thrombo-
cytopenia and major bleeding complications (Table 3, Figure 1).
Discussion
Pulmonary embolism is considered a potentially fatal disease that 
can cause sudden and dramatic death. With the use of  antico-
agulant therapy, the clinical outcome of  such patients has been 
markedly improved [7]. Early initiation of  therapeutic anticoagu-
lation is recommended in all patients with confirmed or highly 
suspected PE while the diagnostic workup is still ongoing [8]. 
Many studies has compared the efficacy and safety of  subcutane-
ous LMWH with those of  unfractionated heparin. Of  these stud-
ies, three major studies [9-11] involving a total of  1951 patients 
with non high risk symptomatic PE or with asymptomatic PE 
in association with symptomatic DVT were enrolled in a meta-
analysis [12]. At the end of  the study treatment, LMWH was at 
least as efficacious as unfractionated heparin regarding the rate of  
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recurrent VTE and at least as safe regarding major bleeding with 
no difference in mortality between the two groups.
The monitoring of  LMWH therapy in pulmonary embolism is 
crucial and helps us to avoid complications such as recurrent 
pulmonary embolism or complications related to anticoagulant 
therapy such as bleeding and thrombocytopenia. In this study, we 
used anti-Xa assay to monitor efficacy and safety of  enoxapa-
rin in the treatment of  pulmonary embolism. Determination of  
the therapeutic ranges of  LMWHs and its correlation to the out-
come have been done for the treatment of  deep-vein thrombosis 
[4] and acute Coronary Syndrome [5] using anti-Xa activity as a 
monitor of  their biological activity. However, there is no study has 
been done correlating anti-Xa assay with the clinical outcome of  
patients with pulmonary embolism treated with LMWH. 
Anti-Xa assay has proved its efficacy compared with a PTT for 
monitoring of  continuous heparin infusion with more expedi-
tious achievement of  therapeutic anticoagulation, less laboratory 
tests and heparin dosage changes and more prolonged mainte-
nance of  the therapeutic levels [13]. Also in heparin resistance, 
dosage escalation can be avoided without compromising efficacy, 
by performing a heparin assay and not increasing the dose if  the 
heparin level is maintained in the therapeutic range [14]. 
In our study, it was found that sub therapeutic anti-Xa was mainly 
associated with inappropriate enoxaparin dose in obese patients 
or suboptimal enoxaparin dose in patients with mild renal im-
Table 1. Baseline Characteristics.
Anti-Xa Levels
< 0.5 IU/mL 
(n=9)
≥ 0.5 and < 1.2 
IU/mL (n=22)
≥ 1.2 IU/mL 
(n=11) P-value
Demographics Age, y 
 Female/male, no
 BMI, kg/m2
65 ± 2.4
4/5
30.1 ± 2.5
64 ± 2.7
10/12
28.3 ± 2.5
64 ± 2.2
4/7
29.6 ± 2.4
0.577
0.698
0.137
Serum creatinine,
mg/dl
1.6 ± 0.3*† 1.2 ± 0.2 1.3 ± 0.2 < 0.001
Pulmonary artery pressure, 
mmHg 50 ± 3.2*† 41 ± 2.7 42 ± 2.5 < 0.001
* Significant difference between the < 0.5 IU/mL group and the ≥ 0.5 and < 1.2 IU/mL group.
† Significant difference between the < 0.5 IU/mL group and the ≥ 1.2 IU/mL group.
‡ Significant difference between the ≥ 1.2 IU/mL group and the ≥ 0.5 and < 1.2 IU/mL group.
Table 2. Risk Factors for Pulmonary Embolism.
Anti-Xa Levels
< 0.5 IU/mL 
(n=9)
≥ 0.5 and < 1.2 IU/
mL (n=22)
≥ 1.2 IU/mL 
(n=11)
P-value
Respiratory failure, n (%) 2 (22.2) 5 (22.7) 3 (27.3) 0.783
Post arrest, n (%) 2 (22.2) 4 (18.2) 1 (9) 0.423
Cerebral stroke, no (%) 1 (11.1) 3 (13.6) 2 (18.2) 0.647
Septic shock, no (%) 3 (33.3) 6 (27.3) 4 (36.4) 0.854
Traumatic brain injury, no (%) 1 (11.1) 4 (18.2) 1 (9) 0.855
Table 3. Complications According anti-Xa Levels Obtained with Enoxaparin.
Anti-Xa Levels
< 0.5 IU/mL 
(n=9)
≥ 0.5 and < 1.2 IU/
mL (n=22)
≥ 1.2 IU/mL 
(n=11)
P-value
Recurrent PE, no (%) 7 (77.8) *† 4 (18.2) 1 (9) 0.001
Death, no (%) 3 (33.3) *† 0 0 0.006
Thrombocytopenia, no (%) 2 (22.2) 3 (13.6) 1 (9) 0.41
Major bleeding, no (%) 0 0 0 -
* Significant difference between the < 0.5 IU/mL group and the ≥ 0.5 and < 1.2 IU/mL group.
† Significant difference between the < 0.5 IU/mL group and the ≥ 1.2 IU/mL group.
‡ Significant difference between the ≥ 1.2 IU/mL group and the ≥ 0.5 and < 1.2 IU/mL group.
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pairment (serum creatinine 1.5-2 mg/dl) and in 2 patients it was 
unexplained lower than therapeutic level even though the patients 
are average body weight, with normal kidney function and receiv-
ing the proper enoxaparin dose as per body weight. In such group 
of  patients with sub therapeutic anti-Xa, the incidence of  recur-
rent pulmonary embolism and mortality ware significantly higher 
than therapeutic anti-Xa group with no significant difference as 
regards bleeding complications or thrombocytopenia incidence. 
That is to say that maintenance of  anti-Xa within the therapeu-
tic range 0.5-1.2 IU/mL was associated with significant reduction 
in the incidence of  recurrent pulmonary embolism and mortality 
rate with no difference in the incidence of  thrombocytopenia or 
bleeding complications as compared with sub therapeutic level.
These results were matching with the large unselected cohort 
study of  patients with UA/NSTEMI treated with enoxaparin in 
which mortality and recurrent ischemic events have been shown 
to be significantly associated with low anti-Xa activity [5].
As regards the group of  patients with anti-Xa level ≥ 1.2 IU/mL 
which included 11 patients, Anti-Xa level was surprisingly high 
in such group was no clear explanation same like the group of  
patients with unexplained low level of  anti-Xa level. In this group, 
it was found that the recurrence rate of  pulmonary embolism, 
mortality rate, thrombocytopenia and bleeding complications 
were not significantly different from the group of  patients with 
therapeutic anti-Xa level.
Conclusion
Anti-Xa assay is a good and reliable test for monitoring the ef-
ficacy of  LMWH therapy using enoxaparin for patients with pul-
monary embolism as regards recurrence and mortality rates of  
pulmonary embolism but it will not monitor safety of  enoxaparin 
therapy as regards incidence of  thrombocytopenia and bleed-
ing complications. That is why patients with pulmonary embo-
lism receiving therapeutic dose of  LMWH enoxaparin should be 
monitored with anti-Xa assay as it correlates well with the clinical 
outcome in such patients.
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Figure 1. Complications According to Anti-Xa Levels Obtained with Enoxaparin.
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